Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1994-8-4
|
| pubmed:abstractText |
This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1458-67
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7912725-Adult,
pubmed-meshheading:7912725-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:7912725-Drug Administration Schedule,
pubmed-meshheading:7912725-Female,
pubmed-meshheading:7912725-Humans,
pubmed-meshheading:7912725-Infusions, Intravenous,
pubmed-meshheading:7912725-Male,
pubmed-meshheading:7912725-Middle Aged,
pubmed-meshheading:7912725-Neoplasms,
pubmed-meshheading:7912725-Paclitaxel,
pubmed-meshheading:7912725-Taxoids,
pubmed-meshheading:7912725-Treatment Outcome
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
|
| pubmed:affiliation |
Service de Médecine et Laboratoire d'Investigation, Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|